Cargando…

Safety and biomarker effects of candesartan in non-hypertensive adults with prodromal Alzheimer’s disease

Observational studies suggest that angiotensin receptor blockers in hypertensive adults are associated with lower post-mortem indicators of Alzheimer’s disease pathology. Candesartan, an angiotensin receptor blocker, has a positive cognitive effect in mild cognitive impairment with hypertension. How...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hajjar, Ihab, Okafor, Maureen, Wan, Limeng, Yang, Zhiyi, Nye, Jonathon A, Bohsali, Anastasia, Shaw, Leslie M, Levey, Allan I, Lah, James J, Calhoun, Vince D, Moore, Reneé H, Goldstein, Felicia C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9683395/ https://www.ncbi.nlm.nih.gov/pubmed/36440097 http://dx.doi.org/10.1093/braincomms/fcac270

Ejemplares similares

Effects of Candesartan vs Lisinopril on Neurocognitive Function in Older Adults With Executive Mild Cognitive Impairment: A Randomized Clinical Trial
por: Hajjar, Ihab, et al.
Publicado: (2020)

Effects of candesartan on cerebral microvascular function in mild cognitive impairment: Results of two clinical trials
por: Henley, Brandon, et al.
Publicado: (2023)

Development of digital voice biomarkers and associations with cognition, cerebrospinal biomarkers, and neural representation in early Alzheimer's disease
por: Hajjar, Ihab, et al.
Publicado: (2023)

Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors
por: Hajjar, Ihab, et al.
Publicado: (2022)

Neurobiological Pathways Linking Acute Mental Stress to Impairments in Executive Function in Individuals with Coronary Artery Disease
por: Moazzami, Kasra, et al.
Publicado: (2021)

Untargeted metabolomics reveal dysregulations in sugar, methionine, and tyrosine pathways in the prodromal state of AD
por: Hajjar, Ihab, et al.
Publicado: (2020)

A feasibility trial of gamma sensory flicker for patients with prodromal Alzheimer's disease
por: He, Qiliang, et al.
Publicado: (2021)

Candesartan in heart failure
por: Ripley, Toni L, et al.
Publicado: (2006)

Cost Effectiveness Analysis of Candesartan Therapy in Comparison to Candesartan-Amlodipine Therapy on Hypertensive Outpatients
por: Baroroh, Faridah, et al.
Publicado: (2019)

Racial Disparity in Cerebrospinal Fluid Amyloid and Tau Biomarkers and Associated Cutoffs for Mild Cognitive Impairment
por: Garrett, Stephanie L., et al.
Publicado: (2019)

Sleep/Wake Behavior and EEG Signatures of the TgF344-AD Rat Model at the Prodromal Stage
por: Kreuzer, Matthias, et al.
Publicado: (2020)

Candesartan—the next anti-amyloid drug?
por: Yasar, Sevil
Publicado: (2022)

Patterns of Co-Occurring Gray Matter Concentration Loss across the Huntington Disease Prodrome
por: Ciarochi, Jennifer Ashley, et al.
Publicado: (2016)

Candesartan cilexetil in the treatment of chronic heart failure
por: Baguet, Jean-Philippe, et al.
Publicado: (2009)

Cardio classics revisited – focus on the role of candesartan
por: De Rosa, Maria Leonarda
Publicado: (2010)

Preparation of Candesartan and Atorvastatin Nanoparticles by Solvent Evaporation (†)
por: Vaculikova, Eliska, et al.
Publicado: (2012)

Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington’s Disease
por: Liu, Jingyu, et al.
Publicado: (2018)

Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats
por: Uhm, Jae-Sun, et al.
Publicado: (2014)

Candesartan could ameliorate the COVID-19 cytokine storm
por: Elkahloun, Abdel G., et al.
Publicado: (2020)

Candesartan cilexetil: COVID-19 pneumonia: case report
Publicado: (2020)

Repurposing Candesartan Cilexetil as Antibacterial Agent for MRSA Infection
por: Xu, Lanlan, et al.
Publicado: (2021)

Population Pharmacokinetics of Candesartan in Patients with Chronic Heart Failure
por: Kassem, Imad, et al.
Publicado: (2020)

Candesartan cilexetil/hydrochlorothiazide combination treatment versus high-dose candesartan cilexetil monotherapy in patients with mild to moderate cardiovascular risk (CHILI Triple T)
por: Bönner, Gerd, et al.
Publicado: (2011)

Oxidative stress predicts cognitive decline with aging in healthy adults: an observational study
por: Hajjar, Ihab, et al.
Publicado: (2018)

Time Perception in Prodromal Alzheimer's Dementia and in Prodromal Dementia With Lewy Bodies
por: Pai, Ming-Chyi, et al.
Publicado: (2021)

FDG PET metabolic signatures distinguishing prodromal DLB and prodromal AD
por: Kantarci, Kejal, et al.
Publicado: (2021)

Magnetic resonance evidence of increased iron content in subcortical brain regions in asymptomatic Alzheimer's disease
por: Lin, Qixiang, et al.
Publicado: (2023)

Understanding the schizophrenia prodrome
por: George, Manju, et al.
Publicado: (2017)

The prodromes of Parkinson's disease
por: Rees, Richard Nathaniel, et al.
Publicado: (2018)

Health-care costs of losartan and candesartan in the primary treatment of hypertension
por: Henriksson, M, et al.
Publicado: (2011)

Candesartan prevents impairment of recall caused by repeated stress in rats
por: Braszko, Jan Józef, et al.
Publicado: (2012)

Design and development and evaluation of candesartan cilexetil liquid filling formulations
por: Deepthi, Y., et al.
Publicado: (2015)

Erratum to: Effects of adriamycin and candesartan on the collagen and elastin of the aorta in rats
por: Uhm, Jae-Sun, et al.
Publicado: (2015)

Development of Orodispersible Tablets of Candesartan Cilexetil-β-cyclodextrin Complex
por: Sravya, Maddukuri, et al.
Publicado: (2013)

Therapeutic of Candesartan and Music Therapy in Diabetic Retinopathy with Depression in Rats
por: Luo, Chengping, et al.
Publicado: (2021)

Evaluation of Ameliorative Effect of Quercetin and Candesartan in Doxorubicin-Induced Cardiotoxicity
por: Majhi, Sagarika, et al.
Publicado: (2022)

High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington’s Disease
por: Ciarochi, Jennifer A., et al.
Publicado: (2018)

Update on the role of candesartan in the optimal management of hypertension and cardiovascular risk reduction
por: Okpechi, Ikechi G, et al.
Publicado: (2010)

Differential clinical profile of candesartan compared to other angiotensin receptor blockers
por: Cernes, Relu, et al.
Publicado: (2011)

The Effect of Polysorbate 20 on Solubility and Stability of Candesartan Cilexetil in Dissolution Media
por: Hoppe, Katarzyna, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_s10et7g0ne55ur31qgji99mm2f